Alpha Teknova, Inc. (TKNO)

Market Cap	214.19M -42.4%
Revenue (ttm)	41.80M +9.3%
Net Income	-17.17M
EPS	-0.32
Shares Out	53.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,752
Open	3.970
Previous Close	3.990
Day's Range	3.890 - 4.200
52-Week Range	1.910 - 6.680
Beta	0.47
Analysts	Buy
Price Target	9.00 (+125.28%)
Earnings Date	May 6, 2026

About TKNO

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and dr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 158
• Stock Exchange: NASDAQ
• Ticker Symbol: TKNO
• Website: https://www.teknova.com

Financial Performance

In 2025, Alpha Teknova's revenue was $40.52 million, an increase of 7.35% compared to the previous year's $37.75 million. Losses were -$17.26 million, -35.47% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for TKNO stock is "Buy." The 12-month stock price target is $9.0, which is an increase of 125.28% from the latest price.

Price Target

$9.0

(125.28% upside)

Analyst Consensus: Buy